Increased number of shares and votes in Medivir

Increased number of shares and votes in Medivir

Medivir AB (OMX: MVIR), a research-based speciality pharmaceutical
company focused on infectious diseases, today announces that  the number
of shares and the number of votes in Medivir have changed as a result of
exercise of employee stock options.

Today, the last trading day of the month, there are in total 26,250,591
shares and 32,190,591 votes in Medivir.

For additional information, please contact;
Rein Piir, CFO & VP Investor Relations, Medivir; +46 8 54683123 or
+46 708 537 292.

About Medivir
Medivir is a research-based specialty pharmaceutical company focused on
the development of high-value treatments for infectious diseases.
Medivir has world class expertise in polymerase and protease drug
targets and drug development. Medivir has a strong R&D portfolio and has
recently launched its first product Xerese™/Xerclear®. Medivir's key
pipeline asset, TMC435, a protease inhibitor, is in phase 2b clinical
development for Hepatitis C and is partnered with Tibotec
Pharmaceuticals. 

Xerese™/Xerclear® is an innovative treatment for cold sores, which has
been approved in both the US and Europe. It is partnered with GSK to be
sold OTC in Europe and Russia and with Meda in North America. Medivir
has retained the Rx rights for Xerclear® in Sweden and Finland. 

For more information about Medivir, please visit the Company's website:
www.medivir.se (http://www.medivir.se)